Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 4/20 | 0.56 |
| ▸ | CDK8 | P49336 | 4/20 | 0.55 |
| ▸ | AXL | P30530 | 4/20 | 0.55 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.55 |
| ▸ | SGK1 | O00141 | 4/20 | 0.49 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15500799 | 0.92 | PDPK1 (0.51) | PDPK1CDK8AXLTNIKSGK1 | |
| SCHEMBL15500789 | 0.92 | AXL (0.52) | PDPK1CDK8AXLTNIKSGK1 | |
| SCHEMBL15500793 | 0.91 | PDPK1 (0.49) | PDPK1CDK8AXLTNIKSGK1 | |
| SCHEMBL15500801 | 0.88 | AXL (0.59) | PDPK1CDK8AXLTNIKSGK1 | |
| SCHEMBL15500798 | 0.87 | NTRK1 (0.60) | KIT | |
| SCHEMBL12338414 | 0.85 | PDPK1 (0.40) | PDPK1CDK8AXLTNIK | |
| SCHEMBL15500795 | 0.85 | AXL (0.48) | PDPK1CDK8AXLTNIKSGK1 | |
| SCHEMBL12338410 | 0.85 | MEN1 (0.42) | PDPK1CDK8AXLTNIKCAMKK2 | |
| SCHEMBL1799005 | 0.84 | AXL (0.63) | PDPK1CDK8AXLTNIKSGK1 | |
| SCHEMBL15500877 | 0.83 | PDPK1 (0.54) | PDPK1CDK8AXLTNIKSGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765819-B1 | AZAINDOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-1765819-B1 | AZAINDOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2014-03-12 | — | — | EP | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| EP-2325184-A1 | Azaindoles useful as inhibitors of protein kinases | Vertex Pharmceuticals Incorporated (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2125801-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
| CN-101228160-A | Azaindoles useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2008-07-23 | — | — | CN | disclosed |
| US-20060122213-A1 | Azaindoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | PDPK1 546/4885CDK8 436/4885AXL 4302/4885 |
| US-20060122213-A1 | Azaindoles useful as inhibitors of protein kinases | PRKDC, ABL1, MAP3K20 | PDPK1 163/4885CDK8 171/4885AXL 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.